Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board

Neogene Therapeutics Appoints Han Lee, Ph.D., MBA, as Chief Financial Officer

Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

Neogene Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA as Chief Operating Officer

Kronos Bio Announces Participation in Upcoming Investor Conferences

IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021

Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting

Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine

IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors

Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma

Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies

Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting